Literature DB >> 10841948

Molecular analysis of CD26-mediated signal transduction in T cells.

J Hühn1, S Ehrlich, B Fleischer, A von Bonin.   

Abstract

CD26 or dipeptidylpeptidase IV (DPP IV) is a cell surface protease involved in T cell activation. It is a type II transmembrane glycoprotein consisting of a large extracellular part, a single transmembrane region and a short cytoplasmic tail without any common signalling motifs. To eluciate the mechanisms involved in CD26-mediated signalling we have constructed C-terminal deletion mutants of the human CD26 molecule and transfected them into murine T cell hybridomas. Stimulation experiments show that most of the extracellular part of CD26 can be deleted without affecting its costimulatory activity. The membrane proximal glycosylation rich region of CD26 is sufficient to transduce costimulatory signals. Activation of T cells via CD26, however, is not mediated by the important T cell receptor associated adaptor proteins LAT and TRIM as shown in colocalization assays.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841948     DOI: 10.1016/s0165-2478(00)00170-x

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

Review 1.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

Review 2.  Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Authors:  Petr Busek; Jonathan S Duke-Cohan; Aleksi Sedo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

Review 3.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

4.  PTH/SDF-1α cotherapy promotes proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells.

Authors:  Lingqian Du; Ruijuan Feng; Shaohua Ge
Journal:  Cell Prolif       Date:  2016-08-14       Impact factor: 6.831

5.  Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency.

Authors:  Eunsun Yoo; Laura A Paganessi; Wasfia A Alikhan; Elizabeth A Paganessi; Frank Hughes; Henry C Fung; Elizabeth Rich; Chu Myong Seong; Kent W Christopherson
Journal:  Transfusion       Date:  2012-08-06       Impact factor: 3.157

6.  Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.

Authors:  Sumaiya Chowdhury; Yiqian Chen; Tsun-Wen Yao; Katerina Ajami; Xin M Wang; Yury Popov; Detlef Schuppan; Patrick Bertolino; Geoffrey W McCaughan; Denise Mt Yu; Mark D Gorrell
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

7.  A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression.

Authors:  Phyu Phyu Khin; Seon-Heui Cha; Hee-Sook Jun; Jong Han Lee
Journal:  Med Hypotheses       Date:  2020-08-14       Impact factor: 1.538

8.  Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

Authors:  Kalpit A Vora; Gene Porter; Roche Peng; Yan Cui; Kellyann Pryor; George Eiermann; Dennis M Zaller
Journal:  BMC Immunol       Date:  2009-04-09       Impact factor: 3.615

Review 9.  Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Carolyn F Deacon
Journal:  Nat Rev Endocrinol       Date:  2020-09-14       Impact factor: 43.330

Review 10.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.